⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
8,982
Total Claims
$4.6M
Drug Cost
789
Beneficiaries
$5,785
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+47%
Cost per patient vs peers
$5,785 vs $3,933 avg
+17%
Brand preference vs peers
59.9% vs 51.2% avg
Brand vs Generic
40% generic
Brand: 5,080 claims · $4.5M
Generic: 3,405 claims · $70K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 917 | $1.1M |
| Dapagliflozin Propanediol | 469 | $396K |
| Empagliflozin | 468 | $378K |
| Insulin Degludec | 355 | $336K |
| Insulin Aspart | 358 | $303K |
| Insulin Glargine,hum.Rec.Anlog | 284 | $215K |
| Tirzepatide | 167 | $191K |
| Insulin Regular, Human | 121 | $185K |
| Dulaglutide | 141 | $165K |
| Insulin Glargine,hum.Rec.Anlog | 197 | $160K |
| Insulin Lispro | 144 | $149K |
| Insulin Aspart | 55 | $104K |
| Liraglutide | 50 | $81K |
| Semaglutide | 69 | $71K |
| Insulin Detemir | 77 | $61K |
Prescribing Profile
Patient Profile
68
Avg Age
64%
Female
1.76
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About